Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 69

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 69
---
 of determining the exchange ratio, the valuation of TELI does not include the full $5,000,000 cash contribution. The actual payments of such amounts following the milestone is not a condition to the closing of the Merger.

Approvals

The Board of Directors of TELO has unanimously approved the Merger Agreement and recommends that shareholders of TELO approve the Merger. Similarly, the Board of Directors of TELO has approved the Merger and recommends that its shareholders vote “FOR” the issuance of shares in connection with the Merger.

Termination

The Merger Agreement provides for termination under certain circumstances, including:

| ● 
 ● 
 ● | Mutual                                                                       
 written consent of TELO and TELI                                             
 Failure                                                                      
 to obtain shareholder approval by TELO and by TELI;                          
 If                                                                           
 the Closing has not occurred by December 31, 2025;                           |
|:--|:-----------------------------------------------------------------------------|
| ● | If                                                                           
 a Governmental Entity has issued a final ruling prohibiting the Closing; and |
| ● | By                                                                           
 one party upon an uncured breach of the Merger Agreement by the other party. |

Treatment of TELI Stock Options

TELI currently has no stock options outstanding.

Treatment of TELI Warrants

Under the terms of the Merger Agreement, each warrant to purchase shares of TELI Common Stock that is outstanding will be converted into and become a warrant to purchase shares of TELO Common Stock and TELO will assume each TELI warrant in accordance with its terms. In addition to the Merger Share Consideration, certain members of TELI collectively hold warrants to purchase a total of 14,250,000 TELI Common Stock (the “Warrants”). The Warrants are exercisable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir at $2.00 per share, for a period of 10-years. At Closing, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the Warrants.

Treatment of TELO Options, RSUs and Warrants

TELO’soutstanding options, RSUs and warrants will not be affected by the Merger.

| 40 |

Representations and Warranties

The Merger Agreement contains representations and warranties that TELO and Merger Sub, on the one hand, and TELI, on the other hand, have made to one another as of specific dates. These representations and warranties have been